Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Roxane Laboratories |
---|---|
Information provided by: | Roxane Laboratories |
ClinicalTrials.gov Identifier: | NCT00702091 |
The objective of this study was to prove the bioequivalence of Ramipril 10 mg capsules under fasting conditions.
Condition | Intervention |
---|---|
Hypertension |
Drug: Ramipril |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study |
Official Title: | A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions |
Enrollment: | 39 |
Study Start Date: | January 2005 |
Study Completion Date: | January 2005 |
Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
CEDRA Clinical Research, LLC | |
Austin, Texas, United States, 78759 |
Principal Investigator: | Daniel V Freeland, D.O. | CEDRA Clinical Research, LLC |
Responsible Party: | Roxane Laboratories, Inc. ( Elizabeth Ernst, Director, DRA-MA ) |
Study ID Numbers: | RAMI-C10-PVFS-1 |
Study First Received: | June 19, 2008 |
Last Updated: | June 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00702091 |
Health Authority: | United States: Food and Drug Administration |
Vascular Diseases Ramipril Hypertension |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |